Andrew Benjamin Nixon, PhD

Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • Ph.D., Wake Forest University, 1997

Publications

Hubbert, Charlotte, Amaris Guardiola, Rong Shao, Yoshiharu Kawaguchi, Akihiro Ito, Andrew Nixon, Minoru Yoshida, Xiao-Fan Wang, and Tso-Pang Yao. “HDAC6 is a microtubule-associated deacetylase.” Nature 417, no. 6887 (May 23, 2002): 455–58. https://doi.org/10.1038/417455a.

PMID
12024216
Full Text

Nixon, Andrew B., Gabriele Grenningloh, and Patrick J. Casey. “The interaction of RGSZ1 with SCG10 attenuates the ability of SCG10 to promote microtubule disassembly.” J Biol Chem 277, no. 20 (May 17, 2002): 18127–33. https://doi.org/10.1074/jbc.M201065200.

PMID
11882662
Full Text

Burgon, P. G., W. L. Lee, A. B. Nixon, E. G. Peralta, and P. J. Casey. “Phosphorylation and nuclear translocation of a regulator of G protein signaling (RGS10).” J Biol Chem 276, no. 35 (August 31, 2001): 32828–34. https://doi.org/10.1074/jbc.M100960200.

PMID
11443111
Full Text

Burgon, P. G., W. L. Lee, A. B. Nixon, P. J. Casey, and E. G. Peralta. “Phosphorylation and nuclear translocation of a regulator of G-protein signaling (RGS10).” Faseb Journal 14, no. 8 (May 11, 2000): A1483–A1483.

Scholars@Duke

Nixon, A. B., J. T. O’Flaherty, J. K. Salyer, and R. L. Wykle. “Acetyl-CoA:1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase is directly activated by p38 kinase.” J Biol Chem 274, no. 9 (February 26, 1999): 5469–73. https://doi.org/10.1074/jbc.274.9.5469.

PMID
10026159
Full Text

Seeds, M. C., A. B. Nixon, R. L. Wykle, and D. A. Bass. “Differential activation of human neutrophil cytosolic phospholipase A2 and secretory phospholipase A2 during priming by 1,2-diacyl- and 1-O-alkyl-2-acylglycerols.” Biochim Biophys Acta 1394, no. 2–3 (November 2, 1998): 224–34. https://doi.org/10.1016/s0005-2760(98)00111-8.

PMID
9795228
Full Text

Nixon, A. B., M. C. Seeds, D. A. Bass, P. K. Smitherman, J. T. O’Flaherty, L. W. Daniel, and R. L. Wykle. “Comparison of alkylacylglycerol vs. diacylglycerol as activators of mitogen-activated protein kinase and cytosolic phospholipase A2 in human neutrophil priming.” Biochim Biophys Acta 1347, no. 2–3 (August 16, 1997): 219–30. https://doi.org/10.1016/s0005-2760(97)00077-5.

PMID
9295167
Full Text

Nixon, A. B., M. C. Seeds, P. K. Smilherman, P. A. Bass, and R. L. Wvkle. “Comparison of alkylacylglycerol (EAG) and diacylglycerol (AAG) as activators of map kjnase(s) and cytosolic PLA2 in human neutrophil priming.” Faseb Journal 10, no. 6 (December 1, 1996).

Scholars@Duke

Nixon, A. B. “Comparison of alkylacylglycerol (eag) and diacylglycerol (aag) as activators of map kinase(s) and cytosolic pla2 in human neutrophil priming.” Faseb Journal 10, no. 6 (December 1, 1996).

Scholars@Duke

O’Flaherty, J. T., M. Kuroki, A. B. Nixon, J. Wijkander, E. Yee, S. L. Lee, P. K. Smitherman, R. L. Wykle, and L. W. Daniel. “5-Oxo-eicosanoids and hematopoietic cytokines cooperate in stimulating neutrophil function and the mitogen-activated protein kinase pathway..” J Biol Chem 271, no. 30 (July 26, 1996): 17821–28. https://doi.org/10.1074/jbc.271.30.17821.

PMID
8663432
Full Text

Pages